Targeted therapies against EGFR and EGFRvIII has yielded mixed results [24] with some showing promising outcomes, however more evidence and work is needed to get a better understanding of EGFR/EGFRvIII pathway, its role in tumor prognosis, and ultimately better targeted therapeutics with improved brain penetration. The gene discussed is EGFR; the disease is neoplasm.